Literature DB >> 2457379

Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues.

D M Tidd1, P Hawley, H M Warenius, I Gibson.   

Abstract

We have investigated the potential for using anti-sense non-ionic methylphosphonate oligonucleotide analogues to study the relationship between oncogene expression and maintenance of the transformed phenotype in malignant cells. Our results confirmed that the methylphosphonates are resistant to biochemical degradation and are devoid of non-specific toxicity towards cultured human HT29 cells. At low temperature (less than 5 degrees C) both N-ras anti-sense and nonsense analogue 9-mers formed 1:1 complexes in solution with an N-ras sense phosphodiester oligodeoxynucleotide 20-mer, but these were largely dissociated at 25 degrees C. Only a fraction (10-20%) of the anti-sense molecules formed stable sequence specific hybrids (Tm 34 degrees C) with the 20-mer. The biological activity of the oligonucleotide analogues was tested in cell culture at 37 degrees C using T15 cells, a line of NIH 3T3 cells transfected with multiple copies of the human N-ras oncogene under control of the glucocorticoid inducible MMTV promoter. On balance the N-ras anti-sense methylphosphonate 9-mer (20-80 microM) had no effect on these cells. In only one of five experiments was an apparent reduction in dexamethasone-induced p21N-ras protein accumulation observed in the presence of the oligonucleotide analogue. Also without effect was an anti-sense 20-mer consisting of a phosphodiester sequence bounded by two methylphosphonate linkages at each end (25-50 microM in culture media; 4.8 microM by microinjection). We conclude from these experiments that, in order to achieve pronounced effects on oncogene expression, it may be necessary to use longer anti-sense methylphosphonate chains, affinity purified for their ability to hybridize with the target sequences.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457379

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  9 in total

1.  Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.

Authors:  R V Giles; D M Tidd
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

Review 2.  New cytotoxic drugs and targets in oncology.

Authors:  J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

3.  Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism.

Authors:  C Boiziau; R Kurfurst; C Cazenave; V Roig; N T Thuong; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

4.  RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds.

Authors:  P J Furdon; Z Dominski; R Kole
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

5.  Effects of RNA secondary structure on cellular antisense activity.

Authors:  T A Vickers; J R Wyatt; S M Freier
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

6.  Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers.

Authors:  L Kibler-Herzog; G Zon; B Uznanski; G Whittier; W D Wilson
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

7.  Sequence dependent effects in methylphosphonate deoxyribonucleotide double and triple helical complexes.

Authors:  L Kibler-Herzog; B Kell; G Zon; K Shinozuka; S Mizan; W D Wilson
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

Review 8.  Antisense technology for cancer therapy: does it make sense?

Authors:  G Carter; N R Lemoine
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

9.  Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.

Authors:  T Saison-Behmoaras; B Tocqué; I Rey; M Chassignol; N T Thuong; C Hélène
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.